Prostate Cancer Clinical Trial
Official title:
Evaluation of [18F] Fluorocholine PET/CT for Detection of Regional Lymph Node Metastases From Prostate Cancer
The objective of this trial is to assess the value of 18F-choline PET/CT for the detection of regional lymph node metastases from prostate cancer. In addition, the investigators want to evaluate whether 18F-choline PET/CT can replace lymphadenectomy for the staging of prostate cancer.
The purpose of this prospective trail is to improve the staging of patients with prostate
cancer. The investigators focus on the group of patients with a newly diagnosed prostate
cancer, and specifically the ones who have an intermediate and high risk of disseminated
prostate cancer.
The aim is to improve staging by replacing the traditional invasive method, the
lymphadenectomy, which has a rather low sensitivity by a non-invasive method, 18F-choline
PET/CT which has a presumably superior sensitivity.
The treatment of patients with prostate cancer relies on the stage of the disease. Patients
with disseminated prostate cancer are incurable and are treated with palliatively. In
contrast, patients with localized prostate cancer are offered curative therapy. Hence, the
stage of prostate cancer is crucial for the choice of treatment.
The potential benefits are
- The patients avoid the surgical trauma including complications and convalescents
period.
- The accuracy of the prostate cancer staging is improved, the potential of which is
better survival.
The patients are 18F-choline PET/CT scanned prior to their lymphadenectomy, the results of
the 18F-choline PET/CT are blinded for the surgeon. The endpoint of the trail is the
comparison of 18F-choline PET/CT and the histopathological investigation of the regional
lymph nodes of prostate.
Assuming a prevalence of metastasised prostate cancer of 20% and a true (unknown)
sensitivity of FCH PET/CT of 95%, 205 patients are sufficient to show that the sensitivity
of the FCH PET/CT is greater than 80% with a power of 80% at significance level 5%. The size
of the confidence interval for specificity of FCH PET/CT is expected to become reasonable
small. In opposition to lymphadenectomy, FCH PET/CT results may point to metastases in
neighbouring regions which gives an additional benefit to FCH PET/CT justifying a test level
for sensitivity of 80%."
Accordingly 205 patients will be included over 2½ years. The first patients have been
included in January 2008. Interim analyses will be done after 25, 50 and 100 patients.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |